Household & Personal Products
Compare Stocks
5 / 10Stock Comparison
EWCZ vs FAT vs SKIN vs IPAR vs COTY
Revenue, margins, valuation, and 5-year total return — side by side.
Restaurants
Household & Personal Products
Household & Personal Products
Household & Personal Products
EWCZ vs FAT vs SKIN vs IPAR vs COTY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Household & Personal Products | Restaurants | Household & Personal Products | Household & Personal Products | Household & Personal Products |
| Market Cap | $273M | $3M | $118M | $3.01B | $2.20B |
| Revenue (TTM) | $211M | $574M | $296M | $1.49B | $5.79B |
| Net Income (TTM) | $11M | $-226M | $-6M | $201M | $-536M |
| Gross Margin | 69.4% | 27.4% | 64.9% | 64.0% | 61.9% |
| Operating Margin | 24.4% | -14.1% | -3.6% | 18.0% | -0.3% |
| Forward P/E | 8.5x | — | — | 19.4x | 9.2x |
| Total Debt | $381M | $1.47B | $379M | $224M | $4.25B |
| Cash & Equiv. | $50M | $23M | $233M | $158M | $257M |
EWCZ vs FAT vs SKIN vs IPAR vs COTY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 21 | May 26 | Return |
|---|---|---|---|
| European Wax Center… (EWCZ) | 100 | 23.9 | -76.1% |
| FAT Brands Inc. (FAT) | 100 | 3.0 | -97.0% |
| The Beauty Health C… (SKIN) | 100 | 3.5 | -96.5% |
| Inter Parfums, Inc. (IPAR) | 100 | 129.5 | +29.5% |
| Coty Inc. (COTY) | 100 | 25.6 | -74.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EWCZ vs FAT vs SKIN vs IPAR vs COTY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EWCZ is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (8.5x vs 9.2x)
- +68.7% vs FAT's -94.2%
FAT ranks third and is worth considering specifically for growth exposure.
- Rev growth 23.4%, EPS growth -98.3%, 3Y rev CAGR 70.8%
- 23.4% revenue growth vs SKIN's -10.0%
- 100.0% yield, vs IPAR's 3.4%, (1 stock pays no dividend)
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
IPAR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.54, yield 3.4%
- 255.2% 10Y total return vs FAT's -14.2%
- Lower volatility, beta 0.54, Low D/E 20.3%, current ratio 2.99x
- Beta 0.54, yield 3.4%, current ratio 2.99x
Among these 5 stocks, COTY doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.4% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (8.5x vs 9.2x) | |
| Quality / Margins | 13.5% margin vs FAT's -39.3% | |
| Stability / Safety | Beta 0.54 vs SKIN's 2.00, lower leverage | |
| Dividends | 100.0% yield, vs IPAR's 3.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +68.7% vs FAT's -94.2% | |
| Efficiency (ROA) | 12.9% ROA vs FAT's -18.0%, ROIC 18.6% vs -3.8% |
EWCZ vs FAT vs SKIN vs IPAR vs COTY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EWCZ vs FAT vs SKIN vs IPAR vs COTY — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EWCZ leads in 1 of 6 categories
IPAR leads 1 • FAT leads 0 • SKIN leads 0 • COTY leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EWCZ leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
COTY is the larger business by revenue, generating $5.8B annually — 27.4x EWCZ's $211M. IPAR is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to FAT's -39.3%. On growth, IPAR holds the edge at +1.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $211M | $574M | $296M | $1.5B | $5.8B |
| EBITDAEarnings before interest/tax | $72M | -$44M | $9M | $291M | $314M |
| Net IncomeAfter-tax profit | $11M | -$226M | -$6M | $201M | -$536M |
| Free Cash FlowCash after capex | $59M | -$75M | $29M | $199M | $311M |
| Gross MarginGross profit ÷ Revenue | +69.4% | +27.4% | +64.9% | +64.0% | +61.9% |
| Operating MarginEBIT ÷ Revenue | +24.4% | -14.1% | -3.6% | +18.0% | -0.3% |
| Net MarginNet income ÷ Revenue | +5.3% | -39.3% | -2.0% | +13.5% | -9.3% |
| FCF MarginFCF ÷ Revenue | +28.1% | -13.1% | +9.8% | +13.3% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.2% | -2.3% | -6.7% | +1.8% | -1.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +182.1% | -23.7% | +38.0% | +2.3% | 0.0% |
Valuation Metrics
Evenly matched — EWCZ and SKIN each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 17.9x trailing earnings, IPAR trades at a 32% valuation discount to EWCZ's 26.5x P/E. On an enterprise value basis, EWCZ's 8.9x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $273M | $3M | $118M | $3.0B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $604M | $1.5B | $264M | $3.1B | $6.2B |
| Trailing P/EPrice ÷ TTM EPS | 26.45x | -0.01x | -5.69x | 17.93x | -5.68x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.47x | — | — | 19.38x | 9.16x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.53x | — |
| EV / EBITDAEnterprise value multiple | 8.88x | — | 7331.15x | 11.33x | 9.36x |
| Price / SalesMarket cap ÷ Revenue | 1.26x | 0.00x | 0.39x | 2.02x | 0.37x |
| Price / BookPrice ÷ Book value/share | 2.98x | — | 2.02x | 2.74x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 4.87x | — | 3.17x | 15.80x | 7.93x |
Profitability & Efficiency
IPAR leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
IPAR delivers a 18.4% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-14 for COTY. IPAR carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), EWCZ scores 7/9 vs FAT's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.7% | — | -9.4% | +18.4% | -14.1% |
| ROA (TTM)Return on assets | +1.6% | -18.0% | -1.2% | +12.9% | -4.7% |
| ROICReturn on invested capital | +8.3% | -3.8% | -6.8% | +18.6% | +2.3% |
| ROCEReturn on capital employed | +7.0% | -5.0% | -4.5% | +23.3% | +2.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 | 7 | 4 | 5 |
| Debt / EquityFinancial leverage | 4.16x | — | 6.20x | 0.20x | 1.07x |
| Net DebtTotal debt minus cash | $331M | $1.5B | $146M | $66M | $4.0B |
| Cash & Equiv.Liquid assets | $50M | $23M | $233M | $158M | $257M |
| Total DebtShort + long-term debt | $381M | $1.5B | $379M | $224M | $4.2B |
| Interest CoverageEBIT ÷ Interest expense | 1.78x | -0.54x | 0.81x | 50.40x | 0.23x |
Total Returns (Dividends Reinvested)
Evenly matched — EWCZ and FAT and IPAR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IPAR five years ago would be worth $14,188 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, EWCZ leads with a +68.7% total return vs FAT's -94.2%. The 3-year compound annual growth rate (CAGR) favors FAT at 6.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +69.2% | -52.3% | -35.0% | +10.9% | -19.6% |
| 1-Year ReturnPast 12 months | +68.7% | -94.2% | -35.9% | -18.8% | -45.3% |
| 3-Year ReturnCumulative with dividends | -67.0% | +21.9% | -91.7% | -32.7% | -79.4% |
| 5-Year ReturnCumulative with dividends | -57.4% | -8.5% | -92.9% | +41.9% | -75.8% |
| 10-Year ReturnCumulative with dividends | -57.4% | -14.2% | -91.6% | +255.2% | -83.0% |
| CAGR (3Y)Annualised 3-year return | -30.9% | +6.8% | -56.4% | -12.4% | -40.9% |
Risk & Volatility
Evenly matched — EWCZ and IPAR each lead in 1 of 2 comparable metrics.
Risk & Volatility
IPAR is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EWCZ currently trades 89.3% from its 52-week high vs FAT's 4.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.56x | 2.00x | 0.54x | 1.08x |
| 52-Week HighHighest price in past year | $6.52 | $3.45 | $2.69 | $142.61 | $5.34 |
| 52-Week LowLowest price in past year | $3.22 | $0.06 | $0.76 | $77.21 | $1.96 |
| % of 52W HighCurrent price vs 52-week peak | +89.3% | +4.7% | +33.8% | +65.9% | +46.8% |
| RSI (14)Momentum oscillator 0–100 | 56.3 | 32.2 | 52.1 | 55.9 | 70.6 |
| Avg Volume (50D)Average daily shares traded | 619K | 85K | 760K | 259K | 7.9M |
Analyst Outlook
Evenly matched — FAT and IPAR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EWCZ as "Hold", SKIN as "Hold", IPAR as "Hold", COTY as "Hold". Consensus price targets imply 60.4% upside for COTY (target: $4) vs -0.3% for EWCZ (target: $6). For income investors, FAT offers the higher dividend yield at 100.00% vs EWCZ's 0.29%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | $5.80 | — | $1.30 | $107.50 | $4.01 |
| # AnalystsCovering analysts | 8 | — | 13 | 19 | 33 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +100.0% | — | +3.4% | +0.6% |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | 5 | 1 |
| Dividend / ShareAnnual DPS | $0.02 | $0.56 | — | $3.20 | $0.02 |
| Buyback YieldShare repurchases ÷ mkt cap | +14.7% | 0.0% | 0.0% | +0.5% | 0.0% |
EWCZ leads in 1 of 6 categories (Income & Cash Flow). IPAR leads in 1 (Profitability & Efficiency). 4 tied.
EWCZ vs FAT vs SKIN vs IPAR vs COTY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EWCZ or FAT or SKIN or IPAR or COTY a better buy right now?
For growth investors, FAT Brands Inc.
(FAT) is the stronger pick with 23. 4% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Inter Parfums, Inc. (IPAR) offers the better valuation at 17. 9x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate European Wax Center, Inc. (EWCZ) a "Hold" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EWCZ or FAT or SKIN or IPAR or COTY?
On trailing P/E, Inter Parfums, Inc.
(IPAR) is the cheapest at 17. 9x versus European Wax Center, Inc. at 26. 5x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — EWCZ or FAT or SKIN or IPAR or COTY?
Over the past 5 years, Inter Parfums, Inc.
(IPAR) delivered a total return of +41. 9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: IPAR returned +255. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EWCZ or FAT or SKIN or IPAR or COTY?
By beta (market sensitivity over 5 years), Inter Parfums, Inc.
(IPAR) is the lower-risk stock at 0. 54β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 267% more volatile than IPAR relative to the S&P 500. On balance sheet safety, Inter Parfums, Inc. (IPAR) carries a lower debt/equity ratio of 20% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — EWCZ or FAT or SKIN or IPAR or COTY?
By revenue growth (latest reported year), FAT Brands Inc.
(FAT) is pulling ahead at 23. 4% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -609. 8% for Coty Inc.. Over a 3-year CAGR, FAT leads at 70. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EWCZ or FAT or SKIN or IPAR or COTY?
Inter Parfums, Inc.
(IPAR) is the more profitable company, earning 11. 3% net margin versus -32. 0% for FAT Brands Inc. — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EWCZ leads at 22. 0% versus -8. 8% for FAT. At the gross margin level — before operating expenses — EWCZ leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EWCZ or FAT or SKIN or IPAR or COTY more undervalued right now?
On forward earnings alone, European Wax Center, Inc.
(EWCZ) trades at 8. 5x forward P/E versus 19. 4x for Inter Parfums, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COTY: 60. 4% to $4. 01.
08Which pays a better dividend — EWCZ or FAT or SKIN or IPAR or COTY?
In this comparison, FAT (100.
0% yield), IPAR (3. 4% yield), COTY (0. 6% yield), EWCZ (0. 3% yield) pay a dividend. SKIN does not pay a meaningful dividend and should not be held primarily for income.
09Is EWCZ or FAT or SKIN or IPAR or COTY better for a retirement portfolio?
For long-horizon retirement investors, Inter Parfums, Inc.
(IPAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 3. 4% yield, +255. 2% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IPAR: +255. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EWCZ and FAT and SKIN and IPAR and COTY?
These companies operate in different sectors (EWCZ (Consumer Defensive) and FAT (Consumer Cyclical) and SKIN (Consumer Defensive) and IPAR (Consumer Defensive) and COTY (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EWCZ is a small-cap quality compounder stock; FAT is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; IPAR is a small-cap deep-value stock; COTY is a small-cap quality compounder stock. FAT, IPAR, COTY pay a dividend while EWCZ, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.